The 18 most recent market catalysts affecting $ELV, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 10, 2026
Corporate Catalyst
Bullish
Impact 75
Elevance Health Stock is Moving Higher After FY26 EPS Reaffirmation
Elevance Health (ELV) reaffirmed its full-year 2026 adjusted earnings guidance, including an underlying adjusted EPS of over $27.00, which is slightly above the analyst consensus. …
Sep 10, 2026
Corporate Catalyst
Bullish
Impact 75
Elevance Health shares are trading higher after the company reaffirmed its FY26 GAAP and adjusted EPS guidance.
Elevance Health's reaffirmation of its FY26 GAAP and adjusted EPS guidance is a significant positive corporate catalyst. It provides clarity and confidence to investors regarding t…
Sep 10, 2026
Corporate Catalyst
Neutral
Impact 65
Elevance Health Affirms FY2026 GAAP EPS expected to be more than $20.10 vs $20.26 Est
Elevance Health (ELV) affirmed its fiscal year 2026 GAAP EPS guidance, stating it expects earnings to be more than $20.10. This is a significant piece of information for investors …
Sep 10, 2026
Corporate Catalyst
Neutral
Impact 75
Elevance Health Affirms FY2026 Adj EPS expected to be more than $27.00 vs $26.91 Est
Elevance Health (ELV) has affirmed its fiscal year 2026 adjusted EPS guidance, indicating it expects to achieve more than $27.00 per share. This is a positive development as it sur…
Aug 21, 2026
Energy/Commodity
Bullish
Impact 85
Elevra Lithium shares are trading higher after the company announced a binding Spodumene Concentrate Supply Agreement with Mangrove for the long-term supply of spodumene concentrate produced at North American Lithium in Québec.
This binding supply agreement is a significant corporate catalyst for Elevra Lithium (ELV), providing revenue visibility and de-risking its operations. For Mangrove (MNGV), it secu…
Jul 17, 2026
Corporate Catalyst
Bullish
Impact 55
Leerink Partners Maintains Market Perform on Elevance Health, Raises Price Target to $395
Leerink Partners analyst Whit Mayo has maintained a 'Market Perform' rating on Elevance Health (ELV) but raised the price target from $364 to $395. This indicates that while the an…
Jul 16, 2026
Corporate Catalyst
Bearish
Impact 55
Wells Fargo Maintains Overweight on Elevance Health, Lowers Price Target to $473
Wells Fargo analyst Stephen Baxter has reiterated an 'Overweight' rating on Elevance Health (ELV), indicating a continued positive long-term view on the company's fundamentals. How…
Jul 16, 2026
Corporate Catalyst
Bullish
Impact 85
These Analysts Revise Their Forecasts On Elevance Health Following Q2 Earnings
Elevance Health's Q2 earnings significantly surpassed analyst expectations, with adjusted earnings of $7.45 per share against an estimated $6.21, and revenue of $49.83 billion exce…
Jul 16, 2026
Corporate Catalyst
Bullish
Impact 55
Guggenheim Maintains Buy on Elevance Health, Raises Price Target to $455
Guggenheim analyst Jason Cassorla has raised the price target for Elevance Health (ELV) from $399 to $455 while maintaining a 'Buy' rating. This action indicates a positive outlook…
Jul 16, 2026
Corporate Catalyst
Bearish
Impact 55
Barclays Maintains Overweight on Elevance Health, Lowers Price Target to $457
Barclays analyst Andrew Mok maintained an 'Overweight' rating on Elevance Health (ELV), signaling continued confidence in the company's long-term prospects. However, the price targ…
Jul 15, 2026
Corporate Catalyst
Bearish
Impact 75
Shares of health insurance companies are trading lower amid sympathy with Elevance after the company reported Q2 financial results that indicated margin pressure.
Elevance's Q2 report, specifically the mention of margin pressure, acts as a significant corporate catalyst for the entire health insurance sector. The 'sympathy' selling suggests …
Jul 15, 2026
Corporate Catalyst
Bearish
Impact 75
Elevance Health shares are trading lower. The company reported Q2 financial results.
The headline directly points to Elevance Health's Q2 financial results as the cause for its share price decline. This is a clear corporate catalyst, indicating that the reported fi…
Jul 15, 2026
Corporate Catalyst
Neutral
Impact 75
Elevance Health Sees FY2026 GAAP EPS expected to be more than $20.10 vs $20.26 Est
Elevance Health (ELV) has released its initial guidance for Fiscal Year 2026 GAAP EPS, stating it expects earnings to be 'more than $20.10'. This is a significant disclosure as it …
Jul 15, 2026
Corporate Catalyst
Neutral
Impact 75
Elevance Health Sees FY2026 Adj EPS expected to be more than $27.00 vs $26.91 Est
Elevance Health (ELV) announced that its adjusted EPS for fiscal year 2026 is expected to exceed $27.00, which is higher than the analyst consensus of $26.91. This positive guidanc…
Jul 15, 2026
Corporate Catalyst
Bearish
Impact 92
Elevance Health Q2 Adj. EPS $7.45 Beats $6.21 Estimate, Sales $49.826B Beat $48.693B Estimate
Elevance Health (ELV) announced Q2 adjusted EPS of $7.45, significantly beating the $6.21 estimate, and sales of $49.826 billion, also exceeding the $48.693 billion estimate. This …
Jul 14, 2026
Corporate Catalyst
Bullish
Impact 55
TD Cowen Maintains Buy on Elevance Health, Raises Price Target to $465
TD Cowen analyst Ryan Langston has maintained a 'Buy' rating on Elevance Health (ELV) and raised the price target from $400 to $465. This action signals increased confidence from t…
Jul 14, 2026
Corporate Catalyst
Bullish
Impact 55
Truist Securities Maintains Buy on Elevance Health, Raises Price Target to $475
Truist Securities analyst David Macdonald maintained a 'Buy' rating on Elevance Health (ELV) and raised the price target from $450 to $475. This action signals continued confidence…
Jul 13, 2026
Corporate Catalyst
Bullish
Impact 55
Wells Fargo Maintains Overweight on Elevance Health, Raises Price Target to $492
Wells Fargo analyst Stephen Baxter has maintained an 'Overweight' rating on Elevance Health (ELV) and raised the price target from $391 to $492. This action signals a strong vote o…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.